World Pharma Today

  Haleon today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon’s Chief Executive Officer commented: “I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon’s significant potential through our new Win as One strategy. “I want to take this opportunity to thank Franck for his sig...

  RHEINFELDEN, Switzerland – Life Science Newswire – Tillotts Pharma AG (“Tillotts”) proudly marks its 15th anniversary as a member of the Japanese Zeria Group, celebrating a period of exceptional growth and valuable collaboration together. The milestone was commemorated in December 2024 with Tillotts’ CEO, Thomas A. Tóth von Kiskér, and members of the leadership team visiting Zeria. During this special occasion, Mr. Sachiaki Ibe, Chairman of the Board of Directors and CEO of Zeria Pharmaceutical Co., Ltd., presented Mr. Tóth a symbolic piece of Japanese art featuring Mount Fuji as a gift to honor Zeria’s appreciation for Tillotts’ remarkable accomplishments since the acquisition. Over the past 15 years, Tillotts has consistently achieved strong double-digit growth and broadened its portfolio while leveraging the trust and support of the Zeria Group. Tillotts’ remarkable success and progress is largely due to the exceptional dedication of its employees, who constantly strive to unl...

  All4Labels Global Packaging Group , a global leader in digital and sustainable labeling solutions, has undertaken a significant expansion of its operations in South Africa. The Group has made strategic investments in infrastructure and technology to enhance its services in the region, marking a milestone in the company’s growth strategy. With the acquisition of a production  site in Durban  18 months ago, All4Labels expanded its market presence in South Africa. Since then, the Group has successfully integrated the facility into its global network, ensuring it aligns with the company’s high standards and operational policies. With this integration now being completed, the site will play a key role in advancing the company’s labeling services in the South African market. The South African region is strategically important for All4Labels as part of its broader growth objectives. The Group is committed to delivering outstanding value to its customers, currently served in th...

  Drug development is a long and complex process that starts with discovery and, if successful, ends with government approval for marketing. Each step in the drug development process, outlined below, has specific goals with the aim of down-selecting appropriate hits and candidates to an approved drug substance. Here, we discuss the relevant objectives and techniques used in each stage of antibody drug development. Discovery The discovery phase is broken down into early and late-stage discovery. The primary goal of the discovery stages is to remove any sequence with undesired performance considering both chemical instabilities and target binding. Discovery will start with a large panel of antibodies that may range from hundreds to thousands and be reduced to a pool in the tens. To reduce the panel, in silico screening is commonly used as a primary tool because sample availability is very scarce at this stage. In silico screening uses computer simulations or virtual screening tools t...

  [LEIDEN, NL] – Life Science Newswire – Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has proudly achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility. Laboratories play a crucial role in advancing healthcare but are among the most resource-intensive environments in the life sciences industry. Synexa is committed to implementing and enhancing sustainability practices throughout the organisation, without any compromise on quality or scientific excellence. Achieving the My Green Lab Certification at the ‘Green’ level will enable Synexa to further support the increasing customer demand for ethical and environmentally conscious clinical studies. The certification process, which commenced in 2024, involved implementing numerous sustainability measures across various departments including lab operations, research practices, supply chain, procurem...

  CPHI & PMEC China (June 24-26 th ) returns to the Shanghai New International Expo Center amid a marked surge in international interest, with industry momentum rebounding following a string of positive developments in global trade and pharmaceutical investment. The 2025 edition is set to become the largest pharma event ever held in Asia, with more than 90,000 attendees and over 12,000 international executives expected. The recent trade tariff reprieve[1], alongside an improving global outlook for pharma – i.e. higher valuations and improved capital expenditure by biotech and big pharma – is transforming into greater international interest at CPHI & PMEC China. International executives will visit the event in record numbers as pharma companies look for new ingredient suppliers and equipment providers. Another key trend emerging is the increasing interest from global pharmaceutical companies in Chinese biotech assets – not only for access to the domestic market, but als...